chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pityriasis rosea; This spontaneous case was received on 28-Oct-2020 from a physician via Health Authority (reference number: SEQW20-04410) with an additional document received on 29-Oct-2020 (being processed together) and concerned a 62-year-old, female patient.   The patient's past medical history included rash. The patient's current medical history was not provided. The patient's historical vaccine included Flucelvax Quadrivalent (influenza vaccine, subunit influenza virus vaccine polyvalent) received on 22-Oct-2018 with no adverse events. The patient's concomitant medications were not reported.  On 10-Oct-2019, the patient was vaccinated with Afluria Quadrivalent (influenza vaccine, indication, dose, route of administration and anatomical location: not reported). The batch number reported was P10019697 (Seqirus batch number: P100109697), expiration date: 22-May-2020.     On an unknown date in 2019, an unknown amount of time after receiving Afluria Quadrivalent, the patient developed rash which was diagnosed as pityriasis rosea by her dermatologist.   The outcome of event was not reported.   The reporter did not provide causality assessment.   This case is linked to case 202005863 (the same patient).  Additional information received on 03-Dec-2020 from physician with additional information (being processed together) received on 07-Dec-2020 via Health Authority (reference number: SEQW20-05538): Historical vaccine from 2018 removed, as it was confirmed that the rash was a month before receiving the flu vaccine. Linked case deleted. Additional reference number added. Narrative was amended accordingly.   Case updated on 15-Apr-2021: Correction made to information received on 03-Dec-2020: Event verbatim and LLT recoded from 'pityriasis' to 'pityriasis rosea', per correction request. Narrative amended accordingly. Company comment updated.  Company comment: The patient experienced pityriasis after administration of Afluria Quadrivalent. Pityriasis rosea is a is a self-limited, inflammatory disease characterized by diffuse, scaling papules or plaques. The cause of pityriasis rosea may be viral infection (some research has implicated human herpesviruses 6, 7, and 8). Drugs may cause a pityriasis rosea-like reaction. Causality is unassessable due to lack of information about reaction onset date.; Sender's Comments: The patient experienced pityriasis after administration of Afluria Quadrivalent. Pityriasis rosea is a is a self-limited, inflammatory disease characterized by diffuse, scaling papules or plaques. The cause of pityriasis rosea may be viral infection (some research has implicated human herpesviruses 6, 7, and 8). Drugs may cause a pityriasis rosea-like reaction. Causality is unassessable due to lack of information about reaction onset date.
Some difficulty breathing; A spontaneous report was received from a consumer who was also a 45-year-old, female patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced some difficulty breathing.   The patient's medical history was not provided. No relevant concomitant medications were reported.   On 11 Jan 2021, approximately one day prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (Lot number: 11J20A) intramuscularly in the left arm for prophylaxis of COVID-19 infection.   On 12 Jan 2021, in the evening, the patient had some difficulty breathing and used her inhaler once. She also reported using her inhaler twice on the same day. Treatment included an inhaler (not specified).  Action taken with mRNA-1273 in response to the event was not reported.  The event, some difficulty breathing, was not resolved.; Reporter's Comments: This case concerns a 45-year old female patient. The medical history is not provided. The patient experienced an unexpected non-serious event of Difficulty breathing approximately one day after receiving their first of two planned doses of mRNA-1273 (Lot number: 11J20A). Based on temporal association between the use of the product and the onset of the event, a causal relationship cannot be excluded and the event is considered possibly related to the vaccine.
Skin peeling like a fungus, rash on arms and feet. DX:  Hearig loss tinea pedis asthma-normal PFT 3/05 tobacco use refraction error. PMH: fall from a 2nd floor 10/03. c/o low back pain.
PATIENT HAS BUMPS ON RIGHT SIDE OF NECK, SHOULDER, HEAD (SMALLPOX GIVEN IN LEFT ARM).
had it before, still gor the shingles/ Suspected vaccination failure; Shingles; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: had it before, still gor the shingles/ Suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: Shingles). The outcome of the vaccination failure was unknown and the outcome of the shingles was not reported.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.     It was unknown if the company considered the vaccination failure and shingles to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 31-MAR-2023 This case was reported by a patient via interactive digital media. The patient reported that he or she received Shingles vaccine and still experienced shingles. The patient stated that no vaccine of any kind for him or her. This case was considered as suspected vaccination failure as details regarding completion of primary schedule, time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting. Follow-up would not possible as no contact details were available.
Big bruises on legs and on arms. Dizziness when turning head or looking up. Hard time standing when dizzy.  Fatigue even after getting full night's sleep.
This spontaneous report as received from a healthcare worker refers to an unspecified patients of unknown age and unknown gender. Since on an unknown date in March 2015, the unspecified patients were vaccinated with improperly stored doses of ROTATEQ (lot# K010221 and expiry date: 12-MAY-2016) (dose and frequency were not reported) for an unknown indication. No adverse effects were reported. No product quality complaint was reported for ROTATEQ. This is one of the several reports from the same reporter. Additional information has been requested.
Telehealth visit for mild fever and rash over body for two days. Pt received MMR and Varicella vaccines on 09/09/2020. Video with mother and infant due to COVID-19 pandemic. Infant's skin is clear now, no fever. Toddler is doing well. No fever, rash, vomiting or diarrhea.
WITHIN ONE WEEK OF RECEIVING H1N1 VACCINE, DEVELOPED SIGNIFICANT ATAXIA, DYSARTHRIA.  FINDINGS SHOWED BRAIN STEM DEMYELINATING SYNDROME POSSIBLE AS A REACTION TO THE FLU SHOT.
After receiving 1st vaccine shot of Pfizer, patient developed mild generalized itching, feeling hot and red patches on left arm.  Benadryl 25 mg was given orally.  After several minutes, she was feeling fine. Er precautions given.
PATIENT RECIEVED A VARICELLA VACCINE ON 11/16/2007, STATED RED & PAINFUL ON 11/17/2007. EXAMED BY DR. NOTED RED, SLIGHTLY RAISED, WARM TO TOUCH AREA LEFT ARM AT SITE VARICELLA VACCINE WAS GIVEN. ADVISED PROBABLE MEDICATION REACTION, NOT ABSESSED OR INFECTED. ADVISED TO APPLY SOLD COMPRESS FOR COMFORT.
Redness/swelling in left deltoid area in AM 03/03/2006.  Treated with Cephalexin.
A day after I had the vaccination, I had weakness, mostly in my right leg, there are some in my left leg. When it first started, you would of thought I was out drinking, that's how bad the walking was. I can hold up my left leg, but when I try to hold up my right leg, at the same level, it starts to come down. From my waist down, I have no pain or nothing. This is so strange, I can hardly walk. When going up the stairs I have to walk: left, then bring up my right, left, then bring up my right.
Severe Diarrhea (>20 times a day) and fatigue lasting 2 weeks; Severe Diarrhea (>20 times a day) and fatigue lasting 2 weeks; This is a spontaneous report from a contactable other hcp (patient). A 20-years-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot Number: EL3248 and expiry date: unknown), dose 2 via an unspecified route of administration on 11Jan2021 at 14:45 as DOSE 2, SINGLE for covid-19 immunisation (age at vaccination: 20-years-old). Medical history included irritable bowel syndrome, IgA Deficiency, depression, anxiety, attention deficit hyperactivity disorder. The patient had no known allergies. Concomitant medications included fluoxetine hydrochloride (PROZAC) and buspirone (BUSPIRONE). The patient historical vaccine includes received bnt162b2, on 21DEC2020 as dose 1 (Batch/Lot Number: EH9899) for covid-19 immunisation (age at vaccination: 20-years-old). The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. The patient experienced severe diarrhea (>20 times a day) and fatigue lasting 2 weeks on 15Jan2021. The patient underwent lab tests and procedures which included sars-cov-2 test: negative on an unknown date (Tested 5 times after 2nd shot, don't remember dates but they were all negative), sars-cov-2 test: negative on an unknown date (Tested 5 times after 2nd shot, don't remember dates but they were all), sars-cov-2 test: negative on an unknown date (Tested 5 times after 2nd shot, don't remember dates but they were all), sars-cov-2 test: negative on an unknown date (Tested 5 times after 2nd shot, don't remember dates but they were all), sars-cov-2 test: negative on an unknown date (Tested 5 times after 2nd shot, don't remember dates but they were all). The event resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken as a result of the events. Outcome of both the events was recovered on an unknown date.  Follow-Up (01Sep2021): Follow-up attempts are completed. No further information is expected.
Administered vaccine that was stored at temperature between -80 degree F to -84 degree F; Administered vaccine that was stored at temperature between -80 degree F to -84 degree F; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT STORAGE ERROR (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F) and POOR QUALITY PRODUCT ADMINISTERED (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F) in a 32-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 076C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Nov-2021 at 3:52 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 16-Nov-2021 at 3:52 PM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F). At the time of the report, PRODUCT STORAGE ERROR (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F) and POOR QUALITY PRODUCT ADMINISTERED (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Vial was stored in frozen storage which was in super cold freezer. On 19-Nov-2021 vial was went from super cold freezer to the refrigerator. 70 vials were still in the ultra cold freezer, 8 vials were in the refrigerator, so a total of 78 vials were affected. Vaccine vial state changes were noticed and vial was never refrozen. None of the vials were punctured before the event. Temperature excursion remained for 1 month. Concomitant medications were not reported. Treatment details were not provided.   This case was linked to MOD-2021-402935 (Patient Link).
Information has been received from a nurse practitioner concerning a nurse who on an unspecified date, in December 2006, was vaccinated with the first dose of VARIVAX (Merck) (lot # not reported).  In July 2007, the patient was vaccinated with the second dose of VARIVAX (Merck) (lot # not reported).  In April 2009, a titer was drawn and it was negative.  The patient had no symptoms.  Additional information has been requested.
05:00 pm slept 15 hours over night.  Slept through 2 alarm clocks.  Arrived at work on time but cognition was significantly slower all day.  Brain got tired with mild headache after 7 hours on shift and went home early, due to could not mentally function to complete work shift.
Tingling in left toe started the night of injection, each day I?ve felt more tingling in lower extremities, most often the left side and some tingling in hands. I have some light tingling in face. The symptoms are better in the morning and feel stronger throughout the day.
Information has been received from a registered nurse concerning a male patient at an elementary school of kindergarten to fourth grade, who on 12/11/1997 was vaccinated with a dose of varicella virus vaccine live (Oka/Merck).  Between 03/01/2004 and 04/05/2004, the patient developed breakthrough varicella.  The patient had more than 50 pox and a temperature of 103.5 for 3 days.  Unspecified medical attention was sought.  A product quality complaint was not involved.  The reporter also mentioned other cases of breakthrough varicella at the same elementary school.  Additional information is not available.
vaginal bloody discharge; arm was little sore; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (arm was little sore) and VAGINAL HAEMORRHAGE (vaginal bloody discharge) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010A21A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure high. Concomitant products included ACETYLSALICYLIC ACID (BABY ASPIRIN) for an unknown indication.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, the patient experienced PAIN IN EXTREMITY (arm was little sore). On 10-Mar-2021, the patient experienced VAGINAL HAEMORRHAGE (vaginal bloody discharge). On 10-Mar-2021, PAIN IN EXTREMITY (arm was little sore) had resolved. At the time of the report, VAGINAL HAEMORRHAGE (vaginal bloody discharge) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Other relevant medication history included high blood pressure medicine.  Patient was using a heating pad . Treatment information was not provided.
Information has been received from a RN concerning a 36 yr old male who on 10Oct05 was vaccinated IM with a 0.5ml dose of pneumococcal 23v polysaccharide vaccine (lot650327/0792P). Concomitant therapy included a dose of influenza virus vaccine (unspecified). On 10Oct05 later that day, the pt experienced a severe localized reaction with soreness, redness, and bruising from the deltoid to the elbow, headache and a fever to 101 deg F. It was noted that the pt also experienced 5 minute episodes of nausea, dyspnea and vertigo a few times that evening. Unspecified medical attention was sought. On 12Oct05, the pt recovered. It was also noted that the pt also had a dose of pneumococcal 23v polysaccharide vaccine the year before. No product quality complaint was involved. Additional information has been requested.
sterile water was used  to reconstitute roatrix instead of the diluent provided; sterile water was used  to reconstitute roatrix instead of the diluent provided; This case was reported by a pharmacist via call center representative and described the occurrence of wrong solution used in drug reconstitution in a patient who received Rota (Rotarix lyophilized formulation) for prophylaxis.   Co-suspect products included rotavirus vaccine oral applicator device (Rotarix Oral Applicator Device) oral applicator for prophylaxis.   On an unknown date, the patient received Rotarix lyophilized formulation and Rotarix Oral Applicator Device. On an unknown date, unknown after receiving Rotarix lyophilized formulation and Rotarix Oral Applicator Device, the patient experienced wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. On an unknown date, the outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The age at vaccination was not reported. The reporter stated that, sterile water was used  to reconstitute roatrix instead of the diluent provided, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. The reporter consented to follow up.
The day after the vaccine I started feeling ill, then developed a 103.5 degree fever. The next day I was having some pain while breathing. I saw my physician of Feb. 2 and was diagnosed with pneumonia for the first time in my life and was given cefpodoxime 200mg tablets to take bid x 10 days. Sorry for the abbreviations, I'm a retired pharmacist. That seemed to clear it up eventually but I still have herpes simplex flares which seems strange since the vaccine was for herpes zoster but maybe there is some association. Anyway, I did not realize I could do my own VAERS report until recently so here it is finally.
This spontaneous report as received from a nurse practitioner refers to a 5-month-old patient of unknown gender. The patient's medical history was not reported. On 19-DEC-2015, the patient was inadvertently vaccinated with a dose of PNEUMOVAX 23 (lot #, dose, route and site of administration were not reported) instead of PREVNAR 13. No product confusion was reported. No adverse effect was reported. Additional information has been requested.
103.0 F + Fever (started ~4pm) sustained for ~12hrs, minimally affected by Advil doses (2 (two) 200 mg capsules every 4 hours until fever broke. (~4 am)   Temperature determined by ear thermometer.  Fever accompanied by severe chills (movement difficulty/stiffness), fatigue, muscle pain. Treated with water and Powerade consumption. Sleep attempted, but not sustained.  Made personal decision to not seek urgent/emergency care (hospital capacity near me and fever did not get above 104.0 F for 3 consecutive readings).
Systemic: Fainting / Unresponsive-Mild, Additional Details: After receiving vaccinations the patient felt faint and as she was walking to her chair she passed out for about 10 seconds. 911 was called and the patient was cleared to leave.
Severe hives (that lasted weeks). I have taken Benadryl and Medrol, but they still have not gone away. Waiting on appointment with allergist.
arm soreness; chills; body aches; feverish; nauseous; throwing up; feel very hot; This is a spontaneous report from a non-contactable consumer (patient). A 26-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL3247), via an unspecified route of administration in Jan2021 at single dose for Covid-19 immunization. The patient's medical history and concomitant medications were not reported. The patient was not diagnosed with COVID-19 prior to vaccination. The patient is not pregnant at the time of vaccination. It was reported that upon administration of the vaccine there was arm soreness that persisted throughout the day. Around 12-14 hours after receiving the vaccine, the patient started having chills, body aches, and felt feverish. The patient also started to feel nauseous as well and ended up throwing up several times. It was reported that the adverse events started on 26Jan2021 (21:00) (as reported). The morning after (date unspecified) the symptoms resolved; however, the patient now feel very hot and the arm soreness was still present. The outcome of events arm soreness and feeling hot was not recovered, while the outcome of other events was recovered in Jan2021. The patient has not been tested for COVID-19 since the vaccination. There was no treatment received for the adverse events. The events were reported as non-serious.  No follow-up attempts are possible. No further information is expected.
11 days after booster shot, developed severe hives that would spontaneously erupt in random areas of body. Are extremely itchy and painful. Today is day 4 and still ongoing. Oral and topical antihistamine administered with little effect. Hives also accompanied by headache and dizziness in days 2-4 and chills. Would go to clinic for treatment and testing if financially able.
3/30 - 16:25 - second COVID19 vaccine does received 3/31 - 3:05 - awoke from sleep with extreme chills, extremely weak, unable to get out of bed, took 400mg of ibuprofen 3/31 - 4:20 - awoke from sleep with extreme sweats, took a cold shower, took 400 mg more of ibuprofen, returned to bed 3/31 - 10:30 - awoke and felt very weak and with joint aches, consumed a tall glass of water, banana, took 600 mg of ibuprofen, returned to bed 3/31 - 15:30 - awoke feeling very weak with persisting joint aches, consumed a turkey sandwich, took 400 mg of ibuprofen, returned to bed 3/31 - 18:30 - awoke feeling better, some joint pain and aching persisting, drank a fruit smoothie, took a hot shower, still felt tired but remained awake 3/31 - 20:45 - fever returned and escalated, felt increased joint and body aches, weakened state, challenging to sit up or stand up from resting position 3/31 - 21:15 - fever measured orally at 102.1degF, took 600mg of ibuprofen and sleep aid, consumed a bowl of miso soup, returned to bed 4/1 - 8:45 - awoke feeling better, no fever, still feeling body aches and joint pain in weakened state, returned to bed 4/1 - 11:55 - awoke feeling similar to earlier, consumed bowl of miso soup, confirmed no fever (98.5degF measured orally) went for a short walk (~.8 mi.)  *additional note: menstruation cycle began 3/30, heavy bleeding normal the first 2 days of cycle*
I woke up with a severe rash covering my entire body. This rash persisted despite over the counter medications. I went to my dermatologist who prescribed a steroid pack. That worked, but as soon as the pack was done the rash came back. I then went to my primary care doctor who prescribed a 10 day stronger steroid. Again, the rash went away but came back once the steroid prescription ended. I then continued to see my dermatologist, went to an allergist to get test and the rash continued to persist. The dermatologist ended up putting me on Zertec double dose and Pepcid double dose. I am still taking this medication 9 months later to keep away the rash. We went through anything that could have caused this and the only thing that had changed was receiving the Covid 19 vaccine.